Potential role of lycopene in the treatment of hepatitis C and prevention of hepatocellular carcinoma

Nutrition and Cancer

Volumn 60, Issue 6, 2008, Pages 729-735

  Seren, Soley ^a   Mutchnick, Milton ^a   Hutchinson, Daryl ^a   Harmanci, Ozgur ^b   Bayraktar, Yusuf ^b   Mutchnick, Sean ^a   Sahin, Kazim ^c   Kucuk, Omer ^a,d,e  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

^c FIRAT UNIVERSITY   (Turkey)

^d KARMANOS CANCER INSTITUTE   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; ALPHA TOCOPHEROL; ANTIOXIDANT; ANTIVIRUS AGENT; BETA CAROTENE; LYCOPENE;

ABSENCE OF SIDE EFFECTS; ANTIOXIDANT ACTIVITY; ANTIVIRAL THERAPY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIETARY INTAKE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; OXIDATIVE STRESS; REVIEW; RISK REDUCTION;

ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; CARCINOMA, HEPATOCELLULAR; CAROTENOIDS; HEPATITIS C, CHRONIC; HUMANS; LIPID PEROXIDATION; LIVER CIRRHOSIS; LIVER NEOPLASMS; OXIDATIVE STRESS;

ANIMALIA; HEPATITIS C VIRUS;

EID: 56249103108     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580802419772     Document Type: Review

References (70)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341, 556-562, 1999.
2. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, et al.: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 28, 930-938, 1998.
3. Davis GL, Albright JE, Cook SF, and Rosenberg DM: Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9, 331-338, 2003.
4. Giovannucci E: A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp Biol Med 227, 852-859, 2002.
5. Schmitz HH, Poor CL, Wellman RB, and Erdman JW Jr.: Concentrations of selected carotenoids and vitamin A in human liver, kidney and lung tissue. J Nutr 121, 1613-1621, 1991.
6. Moxley C, Schwartz SJ, Craft N, DeGroff V, Giovannucci E, et al.: Blood Lycopene Concentrations Increase in Healthy Adults Consuming Standard Servings of Processed Tomato Products Daily. Presented at AICR, Sept. 2-3, Washington, DC, 1999.
7. Fuhrman B, Elis A, and Aviram M: Hypocholesterolemic effect of lycopene and beta-carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages. Biochem Biophysics Res Commun 233, 658-662, 1997.
8. Burton GW and Ingold KU: Beta-carotene: an unusual type of lipid antioxidant. Science 224, 569-573, 1984.
9. Conn PF, Schlach W, and Truscott TG: The singlet oxygen and carotenoid interaction. J Photochem Photobiol 11, 41-47, 1991.
10. DiMascio P, Kaiser S, and Sies H: Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 274, 1-7, 1989.
11. Woodall AA, Britton G, and Jackson MJ: Carotenoids and protection of phospholipids in solution or in liposomes against oxidation by peroxyl radicals: relationship between carotenoid structure and protective ability. Biochim Biophys Acta 1336, 575-586, 1997.
12. Kim Y, DiSilvestro R, and Clinton S: Effects of lycopene-beadlet or tomato-powder feeding on carbon tetrachloride-induced hepatotoxicity in rats. Phytomedicine 11, 152-156, 2004.
13. Koike K: Hepatitis c as a metabolic disease: implication for the pathogenesis of NASH. Hepatology Research 33, 145-150, 2005.
14. Bureau C, Bernad J, Chaouche N, Orfila C, Beraud M, et al.: Non-structural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J Biol Chem 276, 23077-23083, 2001.
15. Pieczenik SR and Neustadt J: Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 83, 84-92 2007.
16. Mihm SS, Fayyazi A, and Ramadori G: Hepatic expression of inducible nitric oxide synthase transcripts in chronic hepatitis C virus infection: relation to hepatic viral load and liver injury. Hepatology 26, 451-458, 1997.
17. Bonkovsky H, Banner BF, and Rothman AL: Iron and chronic viral hepatitis. Hepatology 25, 759-768, 1997.
18. Aust SD, Morehouse LA, and Thomas CE: Role ofmetals in oxygen radical reactions. Free Radic Biol Med 1, 3-25, 1985.
19. Hayasshi H, Takikawa T, Nishimura N, Yano M, Isomura T, et al.: Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 89, 986-988, 1994.
20. Choi J and Ou JH: Mechanisms of liver injury and oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol, Gastrointestinal Liver Physiol 290, 847-851, 2006.
21. Yadav D, Hertan HI, Schweitzer P, Norkus EP, and Pitchumoni CS: Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gastroenterol 97, 2634-2639, 2002.
22. Yamamoto Y, Yamashita S, Fujisawa A, Kokura S, and Yoshikawa T: Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun 247, 166-170, 1998.
23. Rocchi E, Casalgrandi G, Ronzoni A, Rosa MC, Cioni G, et al.: Antioxidant liposoluble vitamins and carotenoids in chronic hepatitis. Eur J Intern Med 12, 116-121, 2001.
24. Di Bisceglie AM: Natural history of hepatitis C: its impact on clinical management. Hepatology 31, 1014-1018, 2000.
25. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, et al.: Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78, 1527-1531, 1997.
26. Rosser BG and Gores GJ: Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology 108, 252-275, 1995.
27. Houglum K, Venkatarmani A, Lyche K, and Chojkier M: A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 113, 1069-1073, 1997.
28. Poli G and Parola M: Oxidative damage and fibrogenesis. Free Radic Biol Med 22, 287-305, 1997.
29. Melhem A, Stern M, Shibolet O, Israeli E, Ackerman Z, et al.: Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol 39, 737-742, 2005.
30. Von Herbay A, Stahl W, Niederau C, and Sies H: Vitamin E improves the aminotransferase status of patients suffering from viral Hepatitis C: a randomized, double-blind, placebo-controlled study. Free Rad Res 27, 599-605, 1997.
31. Mahmood S, Yamada G, Niiyama G, Kawanaka M, Togawa K, et al.: Effect of vitamin E on serum aminotransferasse and thioredoxin levels in patients with viral hepatitis C. Free Radic Res 37, 781-785, 2003.
32. Ideo G, Bellobuono A, Tempini S, Mondazzi L, Riroldi A, et al.: Antioxidant drugs combined with alpha-interferon on chronic hepatitis C not responsive to alpha-interferon alone: a randomized multi-center study. Eur J Gastroenterol Hepatol 11, 1203-1207, 1999.
33. Beloqui O, Prieto J, Suarez M, Gil B, Qian CH, et al.: N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res 13, 279-282, 1993.
34. Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, et al.: Successful interferon theraly reverses enhanced heoatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol 95, 1041-1050, 2000.
35. Harrison SA, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, et al.: Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 3, 604-609, 2005.
36. Volkmann X, Cornberg M, Wedemeyer H, Lehner F, Manns MP, et al.: Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. Hepatology 43, 1311-1316, 2006.
37. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, et al.: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non cirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatogenesis by interferon therapy. Ann Intern Med 131, 174-181, 1999.
38. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al.: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4, 1065-1067, 1998.
39. Nishikawa M, Nishiguchi S, Shiomi S, Tamori A, Koh N, et al.: Somatic mutation of mitochondrial DNA in cancerous and non-cancerous liver tissue in individuals with hepatocellular carcinoma. Cancer Res 61, 1843-1845, 2001.
40. Levrero M: Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25, 3834-3847, 2006.
41. McGlynn KA, Tsao L, Hsing AW, Devesa SS, and Fraumeni JF Jr.: International trends and patterns of primary liver cancer. Int J Cancer 94, 290-296, 2001.
42. El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127, S27-S34, 2004.
43. Parkin DM, Bray FI, and Devesa SS: Cancer burden in the year 2000: the global picture. Eur J Cancer 37, S4-S66, 2001.
44. American Cancer Society: Cancer Facts and Figures - 2004. Vol. 60. Atlanta, GA: American Cancer Society, 2004.
45. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, et al.: Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterology 98, 2060-2063, 2003.
46. Hossain MZ, Wilkens LR, Mehta PP, Loewenstein W, and Bertram JS: Enhancement of gap junctional communication by retinoids correlates with their ability to inhibit neoplastic transformation. Carcinogenesis 10, 1743-1748, 1989.
47. Bertram JS, Pung A, Churley M, Kappock TJ IV, Wilkins LR, et al.: Diverse carotenoids protect against chemically induced neoplastic transformation. Carcinogenesis 12, 671-678, 1991.
48. Levy J, Bosin E, Feldman B, Giat Y, Miinster A, et al.: Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene. Nutr Cancer 24, 257-266, 1995.
49. Rajah R, Valentinis B, and Cohen P: Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta-1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272, 12181-12188, 1997.
50. Mehta P, Bertram JS, and Loewenstein WR: The actions of retinoids on cellular growth correlate with their actions on gap junctional communication. Cell Biol 108, 1053-1065, 1989.
51. Gius D, Botero A, Shah S, and Curry HA: Intracellular oxidation/reduction status in the regulation of transcription factors NF-kappaB and AP-1. Toxicol Lett 106, 93-106, 1999.
52. Riso P, Pinder A, Santangelo A, and Porrini M: Does tomato consumption effectively increase the resistance of lymphocyte DNA to oxidative damage? Am J Clin Nutr 69, 712-718, 1999.
53. Rao AV, Fleshner N, and Agarwal S: Serum and tissue lycopene and biomarkers of oxidation in prostate cancer patients: a case-control study. Nutr Cancer 33, 159-164, 1999.
54. Siler U, Barella L, Spitzer V, Scnorr J, Lein M, et al.: Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. FASEB J 18, 1019-1021, 2004.
55. Hazai E, Bikadi Z, Zsila S, and Lockwood SF: Molecular modeling of the non-covalent binding of the dietary tomato carotenoids lycopene and lycophyl, and selected oxidative metabolites with 5-lipoxygenase. Biorg Medicinal Chem 14, 6859-6867, 2006.
56. Jewell C and O'Brien NM: Effect of dietary supplementation with carotenoids on xenobiotic metabolizing enzymes in the liver, lung, kidney and small intestine of the rat. Br J Nutr 81, 235-242, 1999.
57. Chew BP and Park JS: Carotenoid action on the immune response. J Nutr 134, 257S-261S, 2004.
58. Brienholt V, Lauridsen ST, Daneehvar B, and Jakobeen J: Dose-responses effects of lycopene on selected drug metabolizing and antioxidant enzymes in rat. Cancer Lett 154, 201-210, 2004.
59. Park YO, Hwang ES, and Moon TW: The effect of lycopene on cell growth and oxidative DNA damage of Hep3B human hepatoma cells. Biofactors 23, 129-139, 2005.
60. Hwang ES and Lee HJ: Inhibitory effects of lycopene on the adhesion, invasion, and migration of SK-Hep1 human hepatoma cells. Exp Biol Med (Maywood) 231, 322-327, 2006.
61. Reddy L, Odhav B, and Bhoola K: Aflatoxin B1-induced toxicity in HepG2 cells inhibited by carotenoids: morphology, apoptosis and DNA damage. Biol Chem 387, 87-93, 2006.
62. Yu MW, Chiu YH, Chiang YC, Chen CH, Lee TH, et al.: Plasma carotenoids, glutathione S-transferase M1 and T1 genetic polymorphisms, and risk of hepatocellular carcinoma: independent and interactive effects. Am J Epidemiol 149, 621-629, 1999.
63. Watanabe S, Kitade Y, Masaki T, Nishioka M, Satoh K, et al.: Effects of lycopene and Sho-saiko-to on hepatocarcinogenesis in a rat model of spontaneous liver cancer. Nutr Cancer 39, 96-101, 2001.
64. Takagi H, Kakizaki S, Sohara N, Sato K, Tsukioka G, et al.: Pilot clinical trial of the use of alpha-tocopherol for the prevention of hepatocellular carcinoma in patients with liver cirrhosis. Int J Vitam Nutr Res 73, 411-415, 2003.
65. Yu M, Chiang Y, Lien J, and Chen C: Plasma antioxidant vitamins, chronic hepatitis B virus infection and urinary aflatoxin B1-DNA adducts in healthy males. Carcinogenesis 18, 1189-1194, 1997.
66. Nishino H: Prevention of hepatocellular carcinoma in chronic viral hepatitis patients with cirrhosis by carotenoid mixture: recent results. Cancer Res 174, 67-71, 2007.
67. Astorg P, Gradelet S, Berger R, and Suschetet M: Dietary lycopene decreases the initiation of liver preneoplastic foci by diethylnitrosamine in the rat. Nutr Cancer 29, 60-68, 1997.
68. 1 metabolism. Carcinogenesis 19, 403-411, 1998.
69. Sedjo RL, Papenfuss MR, Craft NE, and Giuliano AR: Effect of plasma micronutrients on clearance of oncogenic HPV infection. Cancer Causes Control 14, 319-326, 2003.
70. Beck MA, Levander OA, and Handy J: Selenium deficiency and viral infection. J Nutr 133, 1463s-1467s, 2003.